Regeneron Announces Upcoming 2016 Investor Conference Presentation
Get Alerts REGN Hot Sheet
Join SI Premium – FREE
TARRYTOWN, N.Y., Feb. 2, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conference:
- Leerink Partners 5th Annual Global Healthcare Conference at 8:30 a.m. Eastern Time on Thursday, February 11, 2016
The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. Archived versions of the presentation will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
|
Investor Relations |
Corporate Communications |
|
Manisha Narasimhan, Ph.D. |
Hala Mirza |
|
914.847.5126 |
914.847.3422 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-2016-investor-conference-presentation-300213556.html
SOURCE Regeneron Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ping An Mobilizes Rapid Response to Typhoon Dolphin
- Canyon GBS Ranks No. 126 on the 2026 Inc. 5000 and No. 11 Among America’s Fastest-Growing Software Companies
- AEG Presents Enters Into Strategic Partnership With Creativeman Productions
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share